• Gastrointestinal hormone measurably improved symptoms of non-alcoholic fatty liver disease

    9 monthes ago - By ScienceDaily

    Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. The findings represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.
    Read more ...